Vor Biopharma (VOR) director submits initial Form 3 with no trades

Rhea-AI Filing Summary

Vor Biopharma Inc. director David Zaccardelli has filed an initial ownership report on Form 3. The filing lists no reportable stock or derivative positions and shows no buy, sell, or other share transactions, indicating this is a baseline regulatory disclosure rather than an active trade.

Key Terms

Form 3, reporting person, derivative securities

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting person regulatory

""reportingPersons": [ { "name": "ZACCARDELLI DAVID""

derivative securities financial

""derivativeSummary": []"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 07/09/2026 - 04:01 PM Accepted by SEC EDGAR 07/09/2026 - 04:01 PM Learn about SEC filing dates

FAQ

What does the Vor Biopharma (VOR) Form 3 filing by David Zaccardelli show?

The Form 3 filing shows director David Zaccardelli’s initial ownership status in Vor Biopharma. It reports no share purchases, sales, or derivative positions, serving purely as a baseline regulatory disclosure of his status as a reporting person.

Are there any share transactions reported in the Vor Biopharma (VOR) Form 3?

No transactions are reported in this Form 3. The transaction summary lists zero buys, zero sells, zero exercises, and no gifts or other dispositions, indicating there has been no recent trading activity tied to this specific filing.

Does the Vor Biopharma (VOR) Form 3 show any derivative securities for David Zaccardelli?

The Form 3 shows no derivative securities for David Zaccardelli. The derivative summary section is empty and derivative transaction counts are zero, meaning no options, warrants, or similar instruments are reported in this initial ownership statement.

What is the purpose of this Vor Biopharma (VOR) Form 3 for investors?

This Form 3 establishes a regulatory baseline for David Zaccardelli as a reporting director at Vor Biopharma. It confirms that, as of this filing, there are no reportable holdings or transactions, helping investors track future insider activity against this starting point.

Does the Vor Biopharma (VOR) Form 3 indicate any indirect ownership or special footnote conditions?

The Form 3 includes a placeholder footnote entry but no substantive details about indirect ownership or voting control. There are no specific notes indicating holdings through trusts, LLCs, or other entities in the data provided from this filing.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ZACCARDELLI DAVID

(Last) (First) (Middle)

500 BOYLSTON STREET, SUITE 1350

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/07/2026

3. Issuer Name and Ticker or Trading Symbol
Vor Biopharma Inc. [ VOR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Adi Osovsky, Attorney-in-Fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)